|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00240292 |
The purpose of this study is to assess the effect of rosuvastatin (up-titrated to a dose of 40mg/day) compared to placebo on cardiac remodelling, estimated by change in left ventricular ejection fraction on radionuclide ventriculography, at 26 weeks post randomisation from baseline.
Condition | Intervention | Phase |
Heart Failure, Congestive |
Drug: Rosuvastatin |
Phase III |
MedlinePlus related topics: | Heart Failure |
ChemIDplus related topics: | Rosuvastatin Rosuvastatin calcium Lipids |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Assess the Impact of Rosuvastatin Treatment for 26 Weeks (Titrated to a Maximum Dose of 40mg Once Daily) on Left Ventricular Function, Cytokines and Lipid Parameters in Patients With Established Systolic Chronic Heart Failure. |
Estimated Enrollment: | 160 |
Study Start Date: | February 2003 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Australia, Australian Capital Territory | |||||
Research Site | |||||
Canberra, Australian Capital Territory, Australia | |||||
Australia, New South Wales | |||||
Research Site | |||||
Sydney, New South Wales, Australia | |||||
Research Site | |||||
Wollongong, New South Wales, Australia | |||||
Research Site | |||||
Newcastle, New South Wales, Australia | |||||
Research Site | |||||
Gosford, New South Wales, Australia | |||||
Australia, Queensland | |||||
Research Site | |||||
Brisbane, Queensland, Australia | |||||
Research Site | |||||
Nambour, Queensland, Australia | |||||
Australia, South Australia | |||||
Research Site | |||||
Adelaide, South Australia, Australia | |||||
Australia, Tasmania | |||||
Research Site | |||||
Launceston, Tasmania, Australia | |||||
Australia, Victoria | |||||
Research Site | |||||
Melbourne, Victoria, Australia | |||||
Research Site | |||||
Geelong, Victoria, Australia | |||||
Research Site | |||||
Mildura, Victoria, Australia | |||||
Australia, Western Australia | |||||
Research Site | |||||
Perth, Western Australia, Australia |
AstraZeneca |
Principal Investigator: | Henry Krum, MBBS PhD FRACP | Clinical Pharmacology, Department of Epidemiology and Preventative Medicine, Monash University, Alfred Hospital |
Study ID Numbers: | 4522AS/0002 |
First Received: | October 16, 2005 |
Last Updated: | October 16, 2005 |
ClinicalTrials.gov Identifier: | NCT00240292 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
|
|
|
|